Acción LGST SEMR PARA
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas SEMR PARA

Acciones

LGST

KYG8028L1077

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Semper Paratus Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
SEMR PARA : Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - Form 8-K
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
Semper Paratus Acquisition Corporation(NasdaqGM:LGST) dropped from NASDAQ Composite Index
Tevogen Bio Inc completed the acquisition of Semper Paratus Acquisition Corporation from a group of shareholders in a reverse merger transaction.
Semper Paratus Acquisition Shareholders Approve Tevogen Bio Deal
Semper Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio
Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq
Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination
Semper Paratus Acquisition : Submission of Matters to a Vote of Security Holders - Form 8-K
Semper Paratus Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement
Semper Paratus Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Semper Paratus Acquisition to Merge With Tevogen Bio; to Bring Tevogen Public
Biotech firm Tevogen Bio enters $1.2 bln SPAC deal for US listing
Biotech firm Tevogen Bio to go public in $1.2 billion SPAC deal
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
Tevogen Bio Inc entered into a merger agreement to acquire Semper Paratus Acquisition Corporation for $1.5 billion in a reverse merger transaction.
Insider Sell: Semper Paratus Acquisition
SEMPER PARATUS ACQUISITION CORP : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción LGST
  4. Noticias SEMR PARA
  5. Otros idiomas